A 15-year, single institution experience of anticoagulation management in paroxysmal nocturnal hemoglobinuria patients on terminal complement inhibition with history of thromboembolism

Am J Hematol. 2022 Feb 1;97(2):E59-E62. doi: 10.1002/ajh.26414. Epub 2021 Nov 29.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Anticoagulants / therapeutic use*
  • Blood Coagulation / drug effects
  • Complement Inactivating Agents / therapeutic use*
  • Disease Management
  • Female
  • Hemoglobinuria, Paroxysmal / blood
  • Hemoglobinuria, Paroxysmal / complications
  • Hemoglobinuria, Paroxysmal / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Thromboembolism / blood
  • Thromboembolism / complications
  • Thromboembolism / drug therapy*

Substances

  • Anticoagulants
  • Complement Inactivating Agents